Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (September 2026)
16 slides from Novo Nordisk A/s Class B's investor day presentation, Sep 21, 2026
Slide 1: International Operations
International Operations Emil Kongshøj Larsen CMD26 EVP, International Operations Capital Markets Day 21 September
Slide 2: Forward-looking statements
2 International Operations Forward-looking statements Novo Nordisk’s statutory Annual Report 2025, Form 20-F, any quarterly financial reports, the materials displayed and other information provided (orally or in writing) at this Capital Markes Day as well as written information released, shown, or o
Slide 3: International Operations aims to be key contributor for overall Novo growth towards 2030 and beyond
3 International Operations International Operations aims to be key contributor for overall Novo growth towards 2030 and beyond Strategic playbook in IO Near-term Long-term Continued significant growth Multi-engine growth DIFFERENTIATE + contribution from injectable semaglutide GLP-1s expected + Aim
Slide 4: IO has delivered double-digit growth over recent years, mainly driven by GLP-1s in EUCAN
4 International Operations IO has delivered double-digit growth over recent years, mainly driven by GLP-1s in EUCAN Obesity sales have been driving the strong growth momentum EUCAN is the key growth region in IO over recent years GLP-1 diabetes Obesity Region EUCAN Region APAC Other diabetes care Bl
Slide 5: The unmet need remains large in IO, while the GLP-1 market continues to grow rapidly
5 International Operations The unmet need remains large in IO, while the GLP-1 market continues to grow rapidly GLP-1 remains a highly attractive market The GLP-1 market is growing rapidly, EUCAN is the largest value market, while insulin is a more mature market while treatment rates remain low Valu
Slide 6: The overall market share has been under pressure due to increased competition
6 International Operations The overall market share has been under pressure due to increased competition Weekly injectable GLP-1 market size and market share development in Dynamics in International Operations International Operations ILLUSTRATIVE Volume market share Weekly injectable GLP-1 patients
Slide 7: EUCAN has encouraging momentum as the share of growth has surpassed the market share
7 International Operations EUCAN has encouraging momentum as the share of growth has surpassed the market share Weekly injectable GLP-1 market size and market share development across regions in Dynamics in EUCAN and rest of International Operations International Operations ILLUSTRATIVE Volume marke
Slide 8: Differentiate semaglutide and expand GLP-1 choice for consumers through accelerated launches
8 International Operations Differentiate semaglutide and expand GLP-1 choice for consumers through accelerated launches Expanded Sub-header Wegovy® 7.2 mg Wegovy® pill Sub-header Ozempic® 2.0 mg choice 2 lines optional 2 lines optional Value Efficacy, approachability and Efficacy, broad label and Ef
Slide 9: High dose Wegovy is gaining traction across Europe, with strong momentum in the UK
9 International Operations High dose Wegovy® is gaining traction across Europe, with strong momentum in the UK Accelerated roll-out plans for Wegovy® 7.2 mg in a single dose pen Significant market share improvements in the UK following the STEP UP publication Weekly injectable GLP-1 obesity volumes
Slide 10: The UK launch of the Wegovy pill is off to a very strong start
10 International Operations The UK launch of the Wegovy® pill is off to a very strong start Wegovy® pill currently available in three major markets Building on the strong initial uptake, Wegovy® pill volumes in the UK has accelerated in recent weeks Cumulative in-market volumes since launch in UK (‘
Slide 11: Novo aims to expand its oral leadership by rolling out the Wegovy pill rapidly in International Operations
11 International Operations Novo aims to expand its oral leadership by rolling out the Wegovy® pill rapidly in International Operations Ambitious roll-out plans for Wegovy® pill in the coming years Diligent approach to roll-out balancing demand and supply ILLUSTRATIVE 1/3 2/3 Majority covered The cu
Slide 12: Telehealth plays a vital role for the obesity expansion plans as Novo surpassed 100 partnerships across IO
12 International Operations Telehealth plays a vital role for the obesity expansion plans as Novo surpassed 100 partnerships across IO We aspire to orchestrate the Go-to-market strategy is shifting to expand telehealth, as seen in the UK and Germany patient journey end-to-end Novo online vs offline
Slide 13: Early loss of exclusivity is managed by focusing on expanding the segment and scaling with partners
13 International Operations Early loss of exclusivity is managed by focusing on expanding the segment and scaling with partners Weekly injectable GLP-1 diabetes sales While prices are declining in the early LoE markets, Novo focuses on expanding volumes growth is driven by the late LoE markets Expan
Slide 14: Ozempic 2.0 mg is currently launched in 10 markets with additional launches expected in the coming months
14 International Operations Ozempic® 2.0 mg is currently launched in 10 markets with additional launches expected in the coming months Ozempic® 2.0 mg rollout plays a vital role Since launch, the combined share of growth in NL and DE have significantly improved to win in the late LoE markets Win ini
Slide 15: IO aims to execute on more than 10 new product launches through 2030
15 International Operations IO aims to execute on more than 10 new product launches through 2030 The future IO portfolio is expected to expand patient reach across therapeutic areas Assets 2026 2027 2028 2029 2030 Ozempic® 2.0 mg Launch CagriSema Launch Additional growth engines Diabetes Awiqli® Lau
Slide 16: IO is a large and growing market with a significant unmet need in both obesity and diabetes
16 International Operations 1 2 3 IO is a large and growing market with a IO is executing on Wegovy® and Ozempic® IO aims to execute on >10 launches significant unmet need in both obesity and high dose launches as well as Wegovy® pill to through 2030, providing a compelling diabetes strengthen compe